Shenzhu Pingxiao formula treats allergic asthma through the HSP90AA1/MAPK14/PTGS2 pathway.

Abstract

OBJECTIVE: Shenzhu Pingxiao formula is a classic Chinese medicinal prescription used for asthma. Given that its mechanism is unclear, this study aimed to evaluate anti-allergic asthma (AA) properties and predict the targets of Shenzhu Pingxiao formula. METHODS: Mice were challenged using house dust mites (HDMs). The anti-AA effect of the formula was evaluated by the airway resistance and number of immune cells in bronchoalveolar lavage fluid (BALF). Network pharmacology and molecular docking were used to predict the targets. The real-time reverse-transcription PCR and western blot were applied to analyze key genes and proteins associated with IL-17 signaling pathway. RESULTS: Administration of formula moderated the number of immune cells and reduced the airway hyperresponsiveness. Administration of formula reduced neutrophil recruitment. HSP90AA1, PTGS2, and MAPK14 involved in IL-17 signaling pathway, were predicted to be key targets for this formula. Vina scores in molecular docking were all ≤ -9 for wogonin-HSP90AA1, wogonin-MAPK14, and wogonin-PTGS2 pairs. Shenzhu Pingxiao formula decreased the expression levels of HSP90AA1, PTGS2, and MAPK14 in HDM-challenged mouse lung. CONCLUSIONS: Shenzhu Pingxiao formula can reduce neutrophil recruitment and exert anti-AA effects via suppression of HSP90AA1/MAPK14/PTGS2 pathway.